Karuna Therapeutics Inc (DELISTED) (KRTX:DL)
329.83
0.00 (0.00%)
USD |
NASDAQ |
Mar 18, 16:00
Karuna Therapeutics Research and Development Expense (TTM): 364.10M for Dec. 31, 2023
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 364.10M |
September 30, 2023 | 347.91M |
June 30, 2023 | 305.91M |
March 31, 2023 | 265.91M |
December 31, 2022 | 224.25M |
September 30, 2022 | 203.34M |
June 30, 2022 | 180.16M |
March 31, 2022 | 151.82M |
December 31, 2021 | 128.20M |
September 30, 2021 | 98.69M |
June 30, 2021 | 72.50M |
Date | Value |
---|---|
March 31, 2021 | 59.17M |
December 31, 2020 | 43.41M |
September 30, 2020 | 32.82M |
June 30, 2020 | 26.02M |
March 31, 2020 | 21.99M |
December 31, 2019 | 24.54M |
September 30, 2019 | 26.26M |
June 30, 2019 | 21.89M |
March 31, 2019 | 17.28M |
December 31, 2018 | 11.54M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
21.89M
Minimum
Jun 2019
364.10M
Maximum
Dec 2023
136.78M
Average
98.69M
Median
Sep 2021
Research and Development Expense (TTM) Benchmarks
Bristol-Myers Squibb Co | 9.673B |
RayzeBio inc (DELISTED) | -- |
Icosavax Inc (DELISTED) | 70.04M |
Madrigal Pharmaceuticals Inc | 272.35M |
Theseus Pharmaceuticals Inc (DELISTED) | 47.22M |